FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969213710> ?p ?o ?g. }

• W2969213710 endingPage "66" @default.
• W2969213710 startingPage "59" @default.
• W2969213710 abstract "BackgroundSingle inhaler triple therapies providing an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting β2-agonist (ICS/LAMA/LABAs) are an emerging treatment option for chronic obstructive pulmonary disease (COPD). Nevertheless, questions remain regarding the optimal patient population for triple therapy as well as the benefit:risk ratio of ICS treatment.MethodsETHOS is an ongoing, randomized, double-blind, multicenter, parallel-group, 52-week study in symptomatic patients with moderate-to-very severe COPD and a history of exacerbation(s) in the previous year. Two doses of single inhaler triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI 320/18/9.6 μg and 160/18/9.6 μg) will be compared to glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg and budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg, all formulated using co-suspension delivery technology. Outcomes include the rate of moderate/severe (primary endpoint) and severe COPD exacerbations, symptoms, quality of life, and all-cause mortality. Sub-studies will assess lung function and cardiovascular safety.Study populationFrom June 2015–July 2018, 16,044 patients were screened and 8572 were randomized. Preliminary baseline demographics show that 55.9% of patients had experienced ≥2 moderate/severe exacerbations in the previous year, 79.1% were receiving an ICS-containing treatment at study entry, and 59.9% had blood eosinophil counts ≥150 cells/mm3.ConclusionsETHOS will provide data on exacerbations, patient-reported outcomes, mortality, and safety in 8572 patients with moderate-to-very severe COPD receiving triple and dual fixed-dose combinations. For the first time, ICS/LAMA/LABA triple therapy with two different doses of ICS will be compared to dual ICS/LABA and LAMA/LABA therapies.Clinical trial registration numberNCT02465567." @default.
• W2969213710 created "2019-08-29" @default.
• W2969213710 creator A5000615749 @default.
• W2969213710 creator A5004903602 @default.
• W2969213710 creator A5020395774 @default.
• W2969213710 creator A5024353071 @default.
• W2969213710 creator A5026538145 @default.
• W2969213710 creator A5027975503 @default.
• W2969213710 creator A5028265360 @default.
• W2969213710 creator A5039653551 @default.
• W2969213710 creator A5068917661 @default.
• W2969213710 creator A5070315113 @default.
• W2969213710 creator A5077419098 @default.
• W2969213710 creator A5078800335 @default.
• W2969213710 creator A5082568705 @default.
• W2969213710 date "2019-10-01" @default.
• W2969213710 modified "2023-09-27" @default.
• W2969213710 title "A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol" @default.
• W2969213710 cites W1890874870 @default.
• W2969213710 cites W1987881697 @default.
• W2969213710 cites W2035374789 @default.
• W2969213710 cites W2038568752 @default.
• W2969213710 cites W2072536470 @default.
• W2969213710 cites W2088797046 @default.
• W2969213710 cites W2101978351 @default.
• W2969213710 cites W2133986277 @default.
• W2969213710 cites W2279631877 @default.
• W2969213710 cites W2324038222 @default.
• W2969213710 cites W2330533577 @default.
• W2969213710 cites W2365138737 @default.
• W2969213710 cites W2513086234 @default.
• W2969213710 cites W2604577460 @default.
• W2969213710 cites W2604743750 @default.
• W2969213710 cites W2783705291 @default.
• W2969213710 cites W2785999277 @default.
• W2969213710 cites W2793035822 @default.
• W2969213710 cites W2802221596 @default.
• W2969213710 cites W2804974357 @default.
• W2969213710 cites W2890960652 @default.
• W2969213710 cites W2891482814 @default.
• W2969213710 cites W2893154769 @default.
• W2969213710 cites W2920797638 @default.
• W2969213710 cites W2964806441 @default.
• W2969213710 doi "https://doi.org/10.1016/j.rmed.2019.08.010" @default.
• W2969213710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31605923" @default.
• W2969213710 hasPublicationYear "2019" @default.
• W2969213710 type Work @default.
• W2969213710 sameAs 2969213710 @default.
• W2969213710 citedByCount "25" @default.
• W2969213710 countsByYear W29692137102019 @default.
• W2969213710 countsByYear W29692137102020 @default.
• W2969213710 countsByYear W29692137102021 @default.
• W2969213710 countsByYear W29692137102022 @default.
• W2969213710 countsByYear W29692137102023 @default.
• W2969213710 crossrefType "journal-article" @default.
• W2969213710 hasAuthorship W2969213710A5000615749 @default.
• W2969213710 hasAuthorship W2969213710A5004903602 @default.
• W2969213710 hasAuthorship W2969213710A5020395774 @default.
• W2969213710 hasAuthorship W2969213710A5024353071 @default.
• W2969213710 hasAuthorship W2969213710A5026538145 @default.
• W2969213710 hasAuthorship W2969213710A5027975503 @default.
• W2969213710 hasAuthorship W2969213710A5028265360 @default.
• W2969213710 hasAuthorship W2969213710A5039653551 @default.
• W2969213710 hasAuthorship W2969213710A5068917661 @default.
• W2969213710 hasAuthorship W2969213710A5070315113 @default.
• W2969213710 hasAuthorship W2969213710A5077419098 @default.
• W2969213710 hasAuthorship W2969213710A5078800335 @default.
• W2969213710 hasAuthorship W2969213710A5082568705 @default.
• W2969213710 hasBestOaLocation W29692137101 @default.
• W2969213710 hasConcept C126322002 @default.
• W2969213710 hasConcept C170493617 @default.
• W2969213710 hasConcept C2776042228 @default.
• W2969213710 hasConcept C2776136866 @default.
• W2969213710 hasConcept C2776623344 @default.
• W2969213710 hasConcept C2776723954 @default.
• W2969213710 hasConcept C2776780178 @default.
• W2969213710 hasConcept C2776804153 @default.
• W2969213710 hasConcept C2776885963 @default.
• W2969213710 hasConcept C2777014857 @default.
• W2969213710 hasConcept C2777419714 @default.
• W2969213710 hasConcept C2779871671 @default.
• W2969213710 hasConcept C2780261241 @default.
• W2969213710 hasConcept C2780667556 @default.
• W2969213710 hasConcept C2908647359 @default.
• W2969213710 hasConcept C2909086917 @default.
• W2969213710 hasConcept C42219234 @default.
• W2969213710 hasConcept C71924100 @default.
• W2969213710 hasConcept C99454951 @default.
• W2969213710 hasConceptScore W2969213710C126322002 @default.
• W2969213710 hasConceptScore W2969213710C170493617 @default.
• W2969213710 hasConceptScore W2969213710C2776042228 @default.
• W2969213710 hasConceptScore W2969213710C2776136866 @default.
• W2969213710 hasConceptScore W2969213710C2776623344 @default.
• W2969213710 hasConceptScore W2969213710C2776723954 @default.
• W2969213710 hasConceptScore W2969213710C2776780178 @default.
• W2969213710 hasConceptScore W2969213710C2776804153 @default.
• W2969213710 hasConceptScore W2969213710C2776885963 @default.
• W2969213710 hasConceptScore W2969213710C2777014857 @default.

• next